First Bank & Trust Sells 3,892 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

First Bank & Trust lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 9.4% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 37,681 shares of the biopharmaceutical company’s stock after selling 3,892 shares during the quarter. Gilead Sciences accounts for 0.7% of First Bank & Trust’s holdings, making the stock its 28th biggest position. First Bank & Trust’s holdings in Gilead Sciences were worth $2,904,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Heritage Wealth Management LLC increased its stake in shares of Gilead Sciences by 54.6% during the 4th quarter. Heritage Wealth Management LLC now owns 368 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 130 shares during the last quarter. Sanctuary Wealth Management L.L.C. purchased a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $33,000. SJS Investment Consulting Inc. increased its stake in shares of Gilead Sciences by 187.9% during the 1st quarter. SJS Investment Consulting Inc. now owns 403 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 263 shares during the last quarter. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Gilead Sciences during the 1st quarter worth approximately $36,000. Finally, Venturi Wealth Management LLC purchased a new position in Gilead Sciences in the 1st quarter valued at approximately $36,000. Institutional investors own 82.33% of the company’s stock.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock traded up $0.02 during trading hours on Monday, hitting $75.69. The company’s stock had a trading volume of 988,841 shares, compared to its average volume of 5,779,474. The business has a 50 day moving average price of $77.28 and a two-hundred day moving average price of $78.79. Gilead Sciences, Inc. has a 12-month low of $61.44 and a 12-month high of $89.74. The company has a market cap of $94.31 billion, a PE ratio of 17.33, a PEG ratio of 0.83 and a beta of 0.37. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.91 and a current ratio of 1.02.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $1.34 EPS for the quarter, missing the consensus estimate of $1.64 by ($0.30). The business had revenue of $6.60 billion during the quarter, compared to analysts’ expectations of $6.45 billion. Gilead Sciences had a net margin of 20.03% and a return on equity of 37.53%. Gilead Sciences’s revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.58 earnings per share. Analysts expect that Gilead Sciences, Inc. will post 6.64 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be given a $0.75 dividend. The ex-dividend date is Thursday, September 14th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 3.96%. Gilead Sciences’s dividend payout ratio is currently 68.97%.

Analysts Set New Price Targets

GILD has been the subject of several analyst reports. Truist Financial reissued a “buy” rating and issued a $91.00 price target on shares of Gilead Sciences in a report on Wednesday, September 6th. Royal Bank of Canada raised their price target on shares of Gilead Sciences from $83.00 to $84.00 and gave the company a “sector perform” rating in a report on Friday, August 4th. Piper Sandler cut their target price on shares of Gilead Sciences from $105.00 to $100.00 and set an “overweight” rating for the company in a research report on Monday, July 24th. Bank of America upgraded shares of Gilead Sciences from a “neutral” rating to a “buy” rating and upped their target price for the stock from $88.00 to $95.00 in a research report on Friday, September 8th. Finally, Cantor Fitzgerald cut their price target on shares of Gilead Sciences from $85.00 to $80.00 and set a “neutral” rating for the company in a research report on Wednesday, July 19th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $90.05.

Insider Buying and Selling

In other news, insider Merdad Parsey sold 1,501 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $76.99, for a total transaction of $115,561.99. Following the transaction, the insider now owns 70,130 shares of the company’s stock, valued at $5,399,308.70. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, insider Merdad Parsey sold 1,501 shares of the stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $76.99, for a total value of $115,561.99. Following the transaction, the insider now owns 70,130 shares of the company’s stock, valued at $5,399,308.70. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 5,000 shares of the stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $80.00, for a total value of $400,000.00. Following the completion of the transaction, the chief financial officer now directly owns 107,587 shares in the company, valued at approximately $8,606,960. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.